6.38
+24.61%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Onconova Therapeutics
Its shares trade under the ticker ONTX. It has been listed since 25 July 2013. In the fiscal year to 31 December 2023, it reported revenue of $226,000 and a net loss of $18.9m. At that date it held total assets of $22.7m and shareholders' equity of $10.7m.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania. The company went IPO on 2013-07-25. The firm operates through the identification and development of oncology therapeutics segment. The company is focused on discovering and developing small molecule drug candidates to treat cancer. The firm has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. The company has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The firm's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Jul 2013
- Employees
- 11
- Website
- onconova.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Onconova Therapeutics Inc has a strong and experienced management team with significant expertise in the biopharmaceutical industry.
- The company's primary strength lies in its innovative drug pipeline, with several promising candidates in various stages of development.
Weaknesses
- Onconova Therapeutics Inc has a relatively small research and development budget compared to some of its larger competitors, which could limit its ability to accelerate the development of its pipeline.
- The company heavily relies on external financing to support its ongoing operations, which introduces financial risk and potential dilution for existing shareholders.
Opportunities
- Onconova Therapeutics Inc operates in a growing market for cancer therapeutics, with increasing demand for innovative and targeted treatments.
- The recent advancements in technology and genomics provide an opportunity for the company to identify and develop personalized therapies for specific patient populations.
Threats
- The biopharmaceutical industry is highly competitive, with larger and more established companies having more resources and market presence.
- Regulatory hurdles and approval processes pose a significant threat, as delays or failures could hinder the commercialization of the company's pipeline candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.